Drug news
NICE recommends Inlyta for Renal Cell Carcinoma - Pfizer
The National Institute for Health and Care Excellence (NICE) has issued new draft guidance recommending Inlyta (axitinib) from Pfizer as an option for treating adults with advanced Renal Cell Carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor - Sutent (sunitinib) from Pfizer or Votrient (pazopanib from GSK - or a cytokine. This follows a previous negative recommendation, which was appealed.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.